# PinkDx

> PinkDx is a privately held biotechnology company developing a clinician-collected vaginal-swab test to help evaluate endometrial cancer in women with abnormal bleeding. It combines whole-transcriptome sequencing and machine learning, has raised $45 million in Series A financing, and is conducting prospective clinical validation ahead of a possible mid-2027 launch.

- **Founded:** 2022
- **Headquarters:** Daly City, United States
- **Founders:** Bonnie Anderson (Co-Founder, Chair and CEO), Giulia C. Kennedy (Co-Founder and Chief Scientific Officer), Timothy McMeekan (Co-Founder, Chief Financial Officer and Chief Business Officer)
- **Products:** Investigational endometrial cancer vaginal-swab test, RNA-based discovery and classifier-development platform
- **Notable:** Announced USD 40 million Series A financing in April 2024., Expanded the same Series A to USD 45 million in January 2025., Published peer-reviewed exploratory vaginal-swab research in the International Journal of Gynecological Cancer in April 2026.

## Products & services

- **Investigational endometrial cancer vaginal-swab test** — Clinician-collected sample analyzed with whole-transcriptome sequencing and machine learning; intended to help rule out endometrial cancer in symptomatic women. In clinical validation, with a possible mid-2027 launch contingent on successful studies.
- **RNA-based discovery and classifier-development platform** — Internal platform integrating clinical cohorts, sequencing, feature engineering and curated biorepositories to develop gynecologic cancer diagnostics; not a separately documented commercial software service.

## Achievements

- Announced USD 40 million Series A financing in April 2024.
- Expanded the same Series A to USD 45 million in January 2025.
- Published peer-reviewed exploratory vaginal-swab research in the International Journal of Gynecological Cancer in April 2026.
- Established a prospective multicenter validation study with 16 sites listed in its August 2026 registry record.

## Latest updates

- **2026-09** — PinkDx republished a Bonnie Anderson interview discussing sample selection, clinical evidence and commercialization.
- **2026-08** — PNK002 registry update lists recruitment ongoing, estimated enrollment 4,500, and estimated primary completion October 30, 2026; none are completed validation results.
- **2026-07** — Columbia described the investigational collection workflow and a possible mid-2027 US launch contingent on successful trials.
- **2026-04** — Peer-reviewed exploratory study published; Good Morning America featured the approach.

## Links

- Website: https://www.pinkdx.com/
- LinkedIn: https://www.linkedin.com/company/pinkdx
- Twitter/X: https://x.com/pinkdxinc
- Instagram: https://www.instagram.com/pinkdxinc/

---

Profile page: https://yespress.io/pinkdx
Published by YesPress — https://yespress.io
Last updated: 2026-09-30